Page last updated: 2024-09-03

n-methylisoindigotin and Carcinoma, Pancreatic Ductal

n-methylisoindigotin has been researched along with Carcinoma, Pancreatic Ductal in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alborzinia, H; Cheng, X; Duvaci, T; Eisenbrand, G; Fredebohm, J; Ghafoory, S; Hafezi, M; Hoheisel, JD; Holenya, P; Kim, JY; Mehrabi, A; Merz, KH; Rafiee, R; Saffari, A; Theobald, J; Wölfl, S	1

Other Studies

1 other study(ies) available for n-methylisoindigotin and Carcinoma, Pancreatic Ductal

Article	Year
Methylisoindigo preferentially kills cancer stem cells by interfering cell metabolism via inhibition of LKB1 and activation of AMPK in PDACs. Molecular oncology, 2016, Volume: 10, Issue:6 Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; Humans; Indoles; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Protein Serine-Threonine Kinases	2016

Article

Year

Methylisoindigo preferentially kills cancer stem cells by interfering cell metabolism via inhibition of LKB1 and activation of AMPK in PDACs.

Molecular oncology, 2016, Volume: 10, Issue:6

Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; Humans; Indoles; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Protein Serine-Threonine Kinases

2016